Alaunos Therapeutics financials
$0.9605−5.83%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $3.0K | $0.00 | $0.00 | $2.0K | $4.0K | $0.00 | $4.0K | $1.0K | $1.0K | $0.00 |
| Gross profit | $0.00 | $0.00 | $3.0K | $0.00 | $0.00 | $2.0K | $4.0K | $0.00 | $4.0K | $1.0K | $1.0K | $0.00 |
| Gross margin | — | — | 100.0% | — | — | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$952.0K | -$1.0M | -$907.0K | -$1.2M | -$1.0M | -$1.1M | -$755.0K | -$1.1M | -$1.2M | -$1.7M | -$7.9M | -$8.7M |
| Net income | -$952.0K | -$1.2M | -$999.0K | -$1.2M | -$1.1M | -$1.1M | -$742.0K | -$1.1M | -$1.1M | -$1.7M | -$7.8M | -$8.5M |
| Net margin | — | — | −33300.0% | — | — | −53650.0% | −18550.0% | — | −28225.0% | −168200.0% | −784300.0% | — |
| Diluted EPS | $-0.41 | $-0.59 | $-0.43 | $-0.55 | $-0.63 | $-0.67 | $-0.46 | $-0.70 | $-0.71 | $-1.05 | $-1.75 | $-5.30 |
| EBITDA | -$943.0K | -$1.0M | -$900.0K | -$1.2M | -$1.0M | -$1.1M | -$756.0K | -$1.1M | -$1.2M | -$1.7M | -$3.1M | -$6.6M |
| Operating cash flow | -$300.0K | -$1.0M | -$552.0K | -$844.0K | -$701.0K | -$772.0K | -$592.0K | -$781.0K | -$1.7M | -$1.9M | -$7.4M | -$6.4M |
| Free cash flow | -$300.0K | -$1.0M | -$553.0K | -$941.0K | -$701.0K | -$772.0K | -$592.0K | -$781.0K | -$1.7M | -$1.9M | -$7.4M | -$6.4M |
| Diluted shares | 2.4M | 1.9M | 2.3M | 2.2M | 1.7M | 1.6M | 1.6M | 1.6M | 1.6M | 1.6M | 4.5M | 1.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $124.0K | $354.0K | $1.4M | $1.9M | $2.9M | $319.0K |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.5M | $1.9M | $3.0M | $3.7M | $4.7M | $2.1M |
| Total liabilities | $864.0K | $595.0K | $813.0K | $921.0K | $1.1M | $1.1M |
| Shareholders' equity | $652.0K | $1.3M | $2.2M | $2.8M | $3.7M | $1.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology